Antibalder

Detailed overview

Antibalder is a GHK-Cu + minoxidil oral research capsule, combining two of the most extensively cited hair-cycle-modulating molecules in the dermatology literature into a single research formulation. GHK (glycyl-L-histidyl-L-lysine) is a tripeptide naturally present in human plasma at micromolar concentrations, where it forms a high-affinity 1:1 complex with copper(II); the bioactive form is GHK-Cu. According to Connectivity-Map analyses the complex modulates the expression of more than 4,000 human genes, with a clear bias toward tissue-remodeling, anti-inflammatory and anti-aging programs; in dermal papilla cells specifically, GHK-Cu upregulates VEGF, FGF-7 and noggin and prolongs anagen. Minoxidil, originally developed as an antihypertensive, is the gold-standard topical and oral drug in pattern hair loss; its sulfate metabolite opens ATP-sensitive potassium channels and markedly upregulates VEGF in the dermal papilla, prolonging anagen and shortening telogen. Recent low-dose oral minoxidil (LDOM) literature has expanded the pharmacology beyond topical applications, with multiple controlled studies demonstrating efficacy at doses orders of magnitude below antihypertensive thresholds. Antibalder pairs these two convergent vascular-and-trophic pathways in fixed unit doses to enable structured experimental work on combined-pathway hair-cycle modulation. Important framing: each molecule is individually well documented, but the fixed oral COMBINATION itself is a research formulation, not an approved drug, and the systemic exposure of the oral minoxidil component warrants medical supervision.